acelyrin poison pill - Search News

Acelyrin Adopts Poison Pill

Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.

Seeking Alpha on MSN · 2d

Acelyrin adopts poison pill as Tang Capital Partners raises stake

Acelyrin (NASDAQ:SLRN) stock in focus as the company adopts a poison pill to counter rapid stock acquisition by Tang Capital Partners. Read more here.

The Business Journals · 3d

Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor

The boards of drug developers Pliant Therapeutics Inc. and Acelyrin Inc. adopted "poison pill" provisions this week aimed at heading off stock-accumulation moves by activist investor Kevin Tang.

BioPharma Dive · 1d

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell and gene therapy pilot appeared to survive.

MarketWatch · 2d

Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake

The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.

Fierce Biotech1d

Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

BioSpace1d

Pliant Pops Poison Pill as Concentra Threat Looms

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

Endpoints News2d

Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies

Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.

Acelyrin: Potential Buyout Led By Concentra Biosciences

Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...

Acelyrin adopts limited-duration stockholder rights plan

ACELYRIN (SLRN) announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results